User:Curtis Bixenstine/Bio460Sandbox

Curtis's User Page

Rose's User Page

Initial Article Assessments from Rglastet
Here are two initial articles that could be improved upon:

Angiogenesis Inhibitor
The article on angiogenesis inhibitors could be modified and improved upon. Much of the basic information is present; however, the section on exogenous drugs requires references. In addition, the section on endogenous inhibitors could benefit from some background information and a completed list of the mechanisms of inhibition (for Meth-1 and Meth-2, canstatin...) | Here is a journal article that discusses the role of canstatin in angiogenesis inhibition.

ADAMTS1
The article on ADAMTS1 is a stub-class article that does not include enough information about this particular enzyme in the ADAMTS family of peptidases. Its various roles could also be elaborated upon, including its role in anti-angiogenesis, which is detailed in this | article. Rglastet (talk) 22:49, 4 February 2014 (UTC)

=Initial Article Assessments from Curtis Bixenstine= Here are two initial articles that could be improved upon:

Angiogenesis Inhibitor
As Rose already pointed out, the article on | angiogenesis inhibitors does not meet the criteria for a good article, at this time. The article is well written, but could definitely be organized more thoughtfully. The | Summary section needs to be changed, as it is unclear what the information given is a summary of. Obviously, the drugs section needs to include some references. | This is a journal article about the use of antiogenesis inhibitors to treat cancer. It could be used to cite some of the information in the "Drugs" section. Lastly, the two lists are close to being stand-alone lists, and they need to be better introduced in the text.

DLL4
The article on the Delta like ligand 4 protein is a stub and could use some expanding. This article, written by a group of pharmacists working for Regeneron Pharmaceuticals about the role of DLL4 during vascular growth and differentiation, would be a good reference to start expanding this article with. Curtis Bixenstine (talk) 00:19, 5 February 2014 (UTC)

=Possible References=

Cancer.gov. National Cancer Institute at the National Institutes of Health; 2011 [cited 16 Feb 2014]. Available from: http://www.cancer.gov/cancertopics/factsheet/Therapy/angiogenesis-inhibitors


 * includes general definitions
 * basic information on angiogenesis and angiogenic inhibitors


 * Role of tyrosine kinase inhibitors in anti-angiogenesis therapy


 * information on endogenous inhibitors
 * specific modes of action of multiple inhibitors derived from ECM or basement membrane protein


 * mechanisms of cancer treatment for endogenous inhibitors


 * includes disadvantages of endogenous angiogenic inhibitors and areas of possible improvement


 * includes information on the use of Bevacizumab, an angiogenesis inhibitor used to treat breast cancer, non-small-cell lung cancer, renal cell carcinoma, and other solid malignancies


 * information on possible disadvantages of using anti-angiogenesis drugs in treating cancer patients; toxicity reports


 * Information on the selected administration of bevacizumab, based on race, age, and medical history

Curtis Bixenstine (talk) 18:21, 20 February 2014 (UTC)
 * more information about the toxicity of bevacizumab,specifically, the mechanism of the drug that could lead to ischemic heart disease

=Outline=

Title: Angiogenesis Inhibitors
 * Introduction
 * Include general information


 * Mode of Action
 * Endogenous Inhibitors
 * Explantation of the role of endogenous inhibitors
 * Table of endogenous inhibitors


 * Exogenous Inhibitors
 * Drugs
 * bevacizumab
 * thalidomide
 * http://toxsci.oxfordjournals.org/content/122/1/1.full
 * cannabinoids
 * Table of exogenous inhibitors
 * Diet


 * Side Effects

=Article Draft=

Endogenous Inhibitors
Angiogenesis is regulated by the activity of endogenous stimulators and inhibitors. Unlike exogenous inhibitors, endogenous inhibitors are found in the body naturally and involved in the day-to-day process of regulating blood vessel formation. Endogenous inhibitors are often derived from the extracellular matrix or basement membrane proteins and function by interfering with endothelial cell formation and migration, endothelial tube morphogenesis, and down-regulation of genes expressed in endothelial cells. During tumor growth, the action of angiogenesis stimulators surpasses the control of angiogenesis inhibitors, allowing for unregulated or less regulated blood vessel growth and formation. Endogenous inhibitors are attractive targets for cancer therapy because they are less toxic and less likely to lead to drug resistance than some exogenous inhibitors.

However, the use of endogenous inhibitors has its disadvantages as well. In animal studies, high doses of inhibitors were required to prevent tumor growth and the use of endogenous inhibitors would likely be long-term.

Bevacizumab
Moreover, significant problems have been discovered with the novel antiangiogenic agent bevacizumab, a recombinant humanised monoclonal antibody to the vascular endothelial growth factor that is widely used in cancer treatment. Research on the exact mechanism of toxicity for bevacizumab is still being done, but it appears that the toxicity profiles of these inhibitors reflect the disturbance of growth factor signalling pathways that are important for maintaining homeostasis. However, this novel drug has shown promising results when combined with standard chemotherapy regimens, bevacizumab has been associated with significant improvements compared with chemotherapy alone in the efficacy end points of overall survival, progression-free survival, and response rates in patients with mCRC (all, P < 0.05). Based on these findings, bevacizumab has been denoted a first-rate option for this disease. Combination bevacizumab regimens have been associated with positive clinical activity in breast cancer, non-small-cell lung cancer, renal cell carcinoma, pancreatic cancer, and soft-tissue sarcoma. Because so much research has been done on this drug in the past 5 years, it will be a main topic of discussion in our article.